Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center grants permission for free access to research in PubMed Central and other repositories. A study published in Immunity analyzed SARS-CoV-2-specific humoral and cellular immunity in 14 COVID-19 convalescent patients. Blood samples from eight newly discharged patients and six follow-up patients showed detectable neutralizing antibodies and T cell responses. Neutralization titers correlated with T cell numbers. The study found that most patients had serum-neutralizing activities, with a strong correlation between neutralizing antibody titers and virus-specific T cells. The research highlights the role of both humoral and cellular immunity in protecting against SARS-CoV-2, providing insights into immune responses and potential vaccine development. The study also indicates that recovered patients can maintain IgG levels for at least two weeks post-discharge. The findings suggest that both B and T cells contribute to immune-mediated protection against viral infections. The research underscores the importance of understanding immune responses in severe cases and has implications for vaccine design. The study was conducted with blood samples from patients and healthy donors, using various assays to detect antibodies and T cell responses. The results show that most patients developed neutralizing antibodies, indicating that viral infection does not suppress adaptive immunity. The study also notes variability in neutralizing antibody titers among patients, with some showing no significant neutralization activity. The research provides a foundation for further analysis of protective immunity against SARS-CoV-2 and understanding the pathogenesis of COVID-19.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center grants permission for free access to research in PubMed Central and other repositories. A study published in Immunity analyzed SARS-CoV-2-specific humoral and cellular immunity in 14 COVID-19 convalescent patients. Blood samples from eight newly discharged patients and six follow-up patients showed detectable neutralizing antibodies and T cell responses. Neutralization titers correlated with T cell numbers. The study found that most patients had serum-neutralizing activities, with a strong correlation between neutralizing antibody titers and virus-specific T cells. The research highlights the role of both humoral and cellular immunity in protecting against SARS-CoV-2, providing insights into immune responses and potential vaccine development. The study also indicates that recovered patients can maintain IgG levels for at least two weeks post-discharge. The findings suggest that both B and T cells contribute to immune-mediated protection against viral infections. The research underscores the importance of understanding immune responses in severe cases and has implications for vaccine design. The study was conducted with blood samples from patients and healthy donors, using various assays to detect antibodies and T cell responses. The results show that most patients developed neutralizing antibodies, indicating that viral infection does not suppress adaptive immunity. The study also notes variability in neutralizing antibody titers among patients, with some showing no significant neutralization activity. The research provides a foundation for further analysis of protective immunity against SARS-CoV-2 and understanding the pathogenesis of COVID-19.